102 related articles for article (PubMed ID: 20227307)
1. Low-dose oral contraceptives in adolescents: how low can you go?
Agostino H; Di Meglio G
J Pediatr Adolesc Gynecol; 2010 Aug; 23(4):195-201. PubMed ID: 20227307
[TBL] [Abstract][Full Text] [Related]
2. Use of hormonal contraception in adolescents: skeletal health issues.
Tolaymat LL; Kaunitz AM
Curr Opin Obstet Gynecol; 2009 Oct; 21(5):396-401. PubMed ID: 19491681
[TBL] [Abstract][Full Text] [Related]
3. Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence.
Cibula D; Skrenkova J; Hill M; Stepan JJ
Eur J Endocrinol; 2012 Jun; 166(6):1003-11. PubMed ID: 22436400
[TBL] [Abstract][Full Text] [Related]
4. Bone accretion in adolescents using the combined estrogen and progestin transdermal contraceptive method Ortho Evra: a pilot study.
Harel Z; Riggs S; Vaz R; Flanagan P; Harel D; Machan JT
J Pediatr Adolesc Gynecol; 2010 Feb; 23(1):23-31. PubMed ID: 19647454
[TBL] [Abstract][Full Text] [Related]
5. Impact of oral contraceptive on bone metabolism.
Trémollieres F
Best Pract Res Clin Endocrinol Metab; 2013 Feb; 27(1):47-53. PubMed ID: 23384745
[TBL] [Abstract][Full Text] [Related]
6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
7. Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period.
Biason TP; Goldberg TB; Kurokawa CS; Moretto MR; Teixeira AS; Nunes HR
BMC Endocr Disord; 2015 Apr; 15():15. PubMed ID: 25990414
[TBL] [Abstract][Full Text] [Related]
8. The effect of hormonal oral contraception on acquisition of peak bone mineral density of adolescents and young women.
Ziglar S; Hunter TS
J Pharm Pract; 2012 Jun; 25(3):331-40. PubMed ID: 22572223
[TBL] [Abstract][Full Text] [Related]
9. Effects of hormonal contraception on bone mineral density after 24 months of use.
Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
[TBL] [Abstract][Full Text] [Related]
10. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density.
Endrikat J; Mih E; Düsterberg B; Land K; Gerlinger C; Schmidt W; Felsenberg D
Contraception; 2004 Mar; 69(3):179-87. PubMed ID: 14969664
[TBL] [Abstract][Full Text] [Related]
11. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study.
Gargano V; Massaro M; Morra I; Formisano C; Di Carlo C; Nappi C
Contraception; 2008 Jul; 78(1):10-5. PubMed ID: 18555812
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
13. [Contraception and bone health in adolescence].
Julen O; Larigaldie S; Yaron M
Rev Med Suisse; 2012 Oct; 8(359):2007-8, 2010. PubMed ID: 23167074
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density.
Gambacciani M; Cappagli B; Lazzarini V; Ciaponi M; Fruzzetti F; Genazzani AR
Maturitas; 2006 May; 54(2):176-80. PubMed ID: 16332417
[TBL] [Abstract][Full Text] [Related]
15. Effect of combined low-dose oral contraceptives on blood viscosity and haematocrit.
Ishak R; Loh Chooi Khim
Malays J Reprod Health; 1991 Jun; 9(1):5-8. PubMed ID: 12317443
[TBL] [Abstract][Full Text] [Related]
16. Oral contraception usage in relation to bone mineral density and bone turnover in adolescent girls.
Lattakova M; Borovsky M; Payer J; Killinger Z
Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):207-14. PubMed ID: 19565418
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study.
Pikkarainen E; Lehtonen-Veromaa M; Möttönen T; Kautiainen H; Viikari J
Contraception; 2008 Sep; 78(3):226-31. PubMed ID: 18692613
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F
Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065
[TBL] [Abstract][Full Text] [Related]
19. [Choosing contraception for adolescents].
Wemeau-jacquemont C
NPN Med; 1985 Feb; 5(84):185-9. PubMed ID: 12280585
[TBL] [Abstract][Full Text] [Related]
20. YAZ and the novel progestin drospirenone.
Mishell DR
J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
